4 results on '"Emily A. Vail"'
Search Results
2. Use of Vasoactive Medications after Cardiac Surgery in the United States
- Author
-
Hannah Wunsch, Emily A. Vail, Penelope S. Pekow, Peter K. Lindenauer, Hayley B. Gershengorn, Meng-Shiou Shieh, and Allan J. Walkey
- Subjects
Pulmonary and Respiratory Medicine ,Inotrope ,Male ,endocrine system ,medicine.medical_specialty ,MEDLINE ,Cardiotonic Agents ,Medicare ,03 medical and health sciences ,0302 clinical medicine ,Vasoactive ,medicine ,Cardiovascular Surgical Procedure ,Humans ,030212 general & internal medicine ,Vasoconstrictor Agents ,Cardiac Surgical Procedures ,Aged ,Retrospective Studies ,Original Research ,business.industry ,Cardiovascular Agents ,United States ,Cardiac surgery ,Treatment Outcome ,030228 respiratory system ,Anesthesia ,Female ,business ,hormones, hormone substitutes, and hormone antagonists - Abstract
Rationale: Patients undergoing cardiac surgery often require vasopressor or inotropic (“vasoactive”) medications, but patterns of postoperative use are not well described. Objectives: This study aimed to describe vasoactive medication administration throughout hospitalization for cardiac surgery, to identify patient- and hospital-level factors associated with postoperative use, and to quantify variation in treatment patterns among hospitals. Methods: Retrospective study using the Premier Healthcare Database. The cohort included adult patients who underwent coronary artery bypass grafting or open valve repair or replacement (or in combination) from January 1, 2016, to June 30, 2018. Primary outcome was receipt of vasoactive medication(s) on the first postoperative day (POD1). We identified patient- and hospital-level factors associated with receipt of vasoactive medications using multilevel mixed-effects logistic regression modeling. We calculated adjusted median odds ratios to determine the extent to which receipt of vasoactive medications on POD1 was determined by each hospital, then calculated quotients of Akaike Information Criteria to compare the relative contributions of patient and hospital characteristics and individual hospitals with observed variation. Results: Among 104,963 adults in 294 hospitals, 95,992 (92.2%) received vasoactive medication(s) during hospitalization; 30,851 (29.7%) received treatment on POD1, most commonly norepinephrine (n = 11,427, 37.0%). A median of 29.0% (range, 0.0–94.4%) of patients in each hospital received vasoactive drug(s) on POD1. After adjustment, hospital of admission was associated with twofold increased odds of receipt of any vasoactive medication on POD1 (adjusted median odds ratio, 2.07; 95% confidence interval, 1.93–2.21). Admitting hospital contributed more to observed variation in POD1 vasoactive medication use than patient or hospital characteristics (quotients of Akaike Information Criteria 0.58, 0.44, and
- Published
- 2020
3. Evaluation of Practice Changes in the Care of Patients with Septic Shock during the U.S. Norepinephrine Shortage
- Author
-
Hannah Wunsch, Gordon D. Rubenfeld, May Hua, Emily A. Vail, Hayley B. Gershengorn, and Allan J. Walkey
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Economic shortage ,Hospital mortality ,030204 cardiovascular system & hematology ,Outcome assessment ,Cohort Studies ,Norepinephrine (medication) ,Norepinephrine ,03 medical and health sciences ,0302 clinical medicine ,Outcome Assessment, Health Care ,Health care ,medicine ,Humans ,Vasoconstrictor Agents ,Hospital Mortality ,Letters ,030212 general & internal medicine ,Practice Patterns, Physicians' ,Septic shock ,business.industry ,medicine.disease ,Shock, Septic ,United States ,Multicenter study ,Shock (circulatory) ,Emergency medicine ,medicine.symptom ,business ,medicine.drug - Published
- 2018
4. Epidemiology of Vasopressin Use for Adults with Septic Shock
- Author
-
Emily A. Vail, Hannah Wunsch, Allan J. Walkey, May Hua, and Hayley B. Gershengorn
- Subjects
Male ,Pulmonary and Respiratory Medicine ,Healthcare database ,medicine.medical_specialty ,Vasopressin ,Databases, Factual ,Vasopressins ,Logistic regression ,03 medical and health sciences ,0302 clinical medicine ,Epidemiology ,Odds Ratio ,Humans ,Vasoconstrictor Agents ,Medicine ,030212 general & internal medicine ,Intensive care medicine ,Original Research ,Aged ,Retrospective Studies ,business.industry ,Septic shock ,030208 emergency & critical care medicine ,Retrospective cohort study ,Middle Aged ,bacterial infections and mycoses ,medicine.disease ,Shock, Septic ,Drug Utilization ,Hospitals ,United States ,Large cohort ,Logistic Models ,Emergency medicine ,Hospital admission ,Drug Therapy, Combination ,Female ,Hypotension ,business - Abstract
Vasopressin may be used to treat vasodilatory hypotension in septic shock, but it is not recommended by guidelines as a first- or second-line agent. Little is known about how often the drug is used currently in septic shock.We conducted this study to describe patterns of vasopressin use in a large cohort of U.S. adults with septic shock and to identify patient and hospital characteristics associated with vasopressin use.This was a retrospective cohort study of adults admitted to U.S. hospitals with septic shock in the Premier healthcare database (July 2008 to June 2013). We performed multilevel mixed-effects logistic regression with hospitals as a random effect to identify factors associated with use of vasopressin alone or in combination with other vasopressors on at least 1 day of hospital admission. We calculated quotients of Akaike Information Criteria (AIC) to determine relative contributions of patient and hospital characteristics to observed variation.Among 584,421 patients with septic shock in 532 hospitals, 100,923 (17.2%) received vasopressin. A total of 6.1% of patients receiving vasopressin received vasopressin alone, and 93.9% received vasopressin in combination with other vasopressors (up to five vasopressors in 15 different combinations). The mean monthly rate of vasopressin use increased from 14.5 to 19.6% over the study period, representing an average annual relative increase of 8% (P 0.001). The median hospital rate of vasopressin use for septic shock was 11.7% (range, 0-69.7%). Patient demographic and clinical characteristics, including patient age (adjusted odds ratio, 0.71 for age 85 yr compared with the reference group of age 50 yr; 95% confidence interval, 0.69-0.74) and acute respiratory dysfunction (adjusted odds ratio, 3.25; 95% confidence interval, 3.20-3.31), were responsible for the majority of observed variation in vasopressin use (quotient of AICs, 0.56). However, hospital of admission also contributed substantially to observed variation (quotient of AICs, 0.37).Approximately one-fifth of patients with septic shock received vasopressin, but rarely as a single vasopressor. The use of vasopressin has increased over time. The likelihood of receiving vasopressin was strongly associated with the specific hospital to which each patient was admitted.
- Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.